FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved Teva's supplemental application for SELARSDI (USTEKINUMAB-AEKN), a biosimilar to ustekinumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Plaque Psoriasis
• Psoriatic Arthritis
• Ulcerative Colitis

Drugs mentioned

• SELARSDI (USTEKINUMAB-AEKN)

Snippet

SUPPL AP for SELARSDI (USTEKINUMAB-AEKN)